WallStSmart

PDD Holdings Inc. (PDD)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PDD Holdings Inc. generates 569% more annual revenue ($418.54B vs $62.58B). PDD leads profitability with a 24.4% profit margin vs 12.4%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).

PDD

Strong Buy

77

out of 100

Grade: B+

Growth: 8.0Profit: 8.5Value: 10.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.53

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PDDUndervalued (+67.8%)

Margin of Safety

+67.8%

Fair Value

$332.33

Current Price

$102.61

$229.72 discount

UndervaluedFair: $332.33Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PDD6 strengths · Avg: 9.8/10
P/E RatioValuation
9.8x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.5%10/10

Every $100 of equity generates 31 in profit

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$45.66B10/10

Generating 45.7B in free cash flow

Altman Z-ScoreHealth
3.5310/10

Safe zone — low bankruptcy risk

Market CapQuality
$139.25B9/10

Large-cap with strong market position

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

PDD0 concerns · Avg: 0/10

No major concerns identified

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : PDD

The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : PDD

No major red flags identified for PDD, but monitor valuation.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

PDD profiles as a mature stock while PFE is a declining play — different risk/reward profiles.

PFE carries more volatility with a beta of 0.41 — expect wider price swings.

PDD is growing revenue faster at 9.0% — sustainability is the question.

PDD generates stronger free cash flow (45.7B), providing more financial flexibility.

Bottom Line

PDD scores higher overall (77/100 vs 49/100), backed by strong 24.4% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

PDD Holdings Inc.

CONSUMER CYCLICAL · INTERNET RETAIL · China

Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?